Short telomeres are a risk factor for idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Idiopathic interstitial pneumonias (IIPs) have a progressive and often fatal course, and their enigmatic etiology has complicated approaches to effective therapies. Idiopathic pulmonary fibrosis (IPF) is the most common of IIPs and shares with IIPs an increased incidence with age and unexplained scarring in the lung. Short telomeres limit tissue renewal capacity in the lung and germ-line mutations in telomerase components, hTERT and hTR , underlie inheritance in a subset of families with IPF. To examine the hypothesis that short telomeres contribute to disease risk in sporadic IIPs, we recruited patients who have no family history and examined telomere length in leukocytes and in alveolar cells. To screen for mutations, we sequenced hTERT and hTR. We also reviewed the cases for features of a telomere syndrome. IIP patients had shorter leukocyte telomeres than age-matched controls ( P < 0.0001). In a subset (10%), IIP patients had telomere lengths below the first percentile for their age. Similar to familial cases with mutations, IPF patients had short telomeres in alveolar epithelial cells ( P < 0.0001). Although telomerase mutations were rare, detected in 1 of 100 patients, we identified a cluster of individuals (3%) with IPF and cryptogenic liver cirrhosis, another feature of a telomere syndrome. Short telomeres are thus a signature in IIPs and likely play a role in their age-related onset. The clustering of cryptogenic liver cirrhosis with IPF suggests that the telomere shortening we identify has consequences and can contribute to what appears clinically as idiopathic progressive organ failure in the lung and the liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, patients with IPF who have mutant telomerase genes are at an increased risk of developing bone marrow failure and liver disease54,71.”
From The telomere syndromes (2012) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, telomere dysfunction in epithelial cells, or perhaps another cell type, might cause parenchymal organ remodelling, which manifests as fibrosis and/or emphysema46,54,99.”
From The telomere syndromes (2012) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moreover, circulating leukocytes and alveolar epithelial cells show shorter telomeres than age-matched individuals53.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“The frequency of these mutations is highest in individuals with the progressive disorder IPF, which accounts for 8–15% of familial and 1–3% of sporadic cases54,56,68,69.”
From The telomere syndromes (2012) · cites this paper as [54]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Lead SNPs at two loci (TERC and TERT) associate with several cancers and other diseases, including idiopathic pulmonary fibrosis.”
From Identification of seven loci affecting mean telomere length and their association with disease (2013) · cites this paper as [26]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Telomerase Catalytic Subunit Homologs from Fission Yeast and Human
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., & Cech, T. R. (1997) · Science · doi:10.1126/science.277.5328.955 · Cited by 2,256
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Self-citationTelomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357 · cited 6×
“In IPF families with telomerase mutations, cases of aplastic anemia can be hidden and are uncovered after a thorough family history, suggesting that mutations in telomerase have heterogeneous manifestations in an individual patient and within families, and that a subset of families with IPF falls on the same spectrum…”
BackgroundInfluentialSelf-citationEssential role of mouse telomerase in highly proliferative organs
Lee, H.-W., Blasco, M. A., Gottlieb, G. J., Horner, J. W., Greider, C. W., & DePinho, R. A. (1998) · Nature · doi:10.1038/33345 · Cited by 1,270
A telomerase component is defective in the human disease dyskeratosis congenita
Mitchell, J. R., Wood, E., & Collins, K. (1999) · Nature · doi:10.1038/990141 · Cited by 1,168
Greider, C. W., & Blackburn, E. H. (1987) · Cell · doi:10.1016/0092-8674(87)90576-9 · Cited by 1,150
Cited by
Items 301–400 of 802
Autophagy in pulmonary fibrosis: friend or foe?
Hill, C. N., & Wang, Y. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.09.008 · Cited by 52
Gu, B., Fan, J., Bessler, M., & Mason, P. J. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00674.x · Cited by 44
“Telomere shortening has been thought to be the major contributor to pulmonary fibrosis in these patients (Alder et al., 2008) but perhaps increased sensitivity to oxidative stress plays an additional role in pathogenesis.”
BackgroundTelomere length and telomerase complex mutations in pediatric acute myeloid leukemia
Aalbers, A. M., Calado, R. T., Young, N. S., Zwaan, C. M., Wu, C. O., Kajigaya, S., Coenen, E. A., Baruchel, A., Geleijns, K. P. W., de Haas, V., et al. (2013) · Leukemia · doi:10.1038/leu.2013.57 · Cited by 44
Autoantibodies targeting telomere-associated proteins in systemic sclerosis
Adler, B. L., Boin, F., Wolters, P. J., Bingham, C. O., Shah, A. A., Greider, C. W., Casciola-Rosen, L. A., & Rosen, A. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218918 · Cited by 45
Combined pulmonary fibrosis and emphysema: How does cohabitation affect respiratory functions?
Çiftçi, F., Gülpınar, B., Atasoy, Ç., Kayacan, O., & Saryal, S. (2019) · Advances in Medical Sciences · doi:10.1016/j.advms.2019.03.005 · Cited by 46
Gaysinskaya, V. A., Stanley, S. E., Adam, S. S., & Armanios, M. Y. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.07.025 · Cited by 43
Self-citationTelomeres in Interstitial Lung Disease
Stock, C. J. W., & Renzoni, E. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071384 · Cited by 47
“Shorter TLs are described in AT2 cells of IPF lungs compared to controls, although interestingly this was observed regardless of the presence of mutations [24].”
BackgroundPathogenesis of idiopathic pulmonary fibrosis and its clinical implications
Spagnolo, P., Rossi, G., & Cavazza, A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.917050 · Cited by 47
“Mutations within telomerase-associated genes (telomerase reverse transcriptase component [TERT] and RNA template component [TERC]) account for approximately 10% of familial and 1–3% of sporadic IPF cases [20], although short telomere length is a more common finding in IPF and is observed also in patients who do not ca…”
BackgroundMcErlean, P. K., Bell, C. G., Hewitt, R. J., Busharat, Z., Ogger, P. P., Ghai, P., Albers, G. J., Calamita, E., Kingston, S., Molyneaux, P. L., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202101-0004oc · Cited by 48
“Advanced age is a key risk factor for IPF(44), and numerous studies have shown that molecular changes commonly associated with aging such as telomere shortening (45, 46) and augmented markers of senescence (47, 48) are found in IPF patients.”
BackgroundReciprocal interactions between alveolar progenitor dysfunction and aging promote lung fibrosis
Liang, J., Huang, G., Liu, X., Taghavifar, F., Liu, N., 姚昌富, Deng, N., Wang, Y., Burman, A., Xie, T., et al. (2023) · eLife · doi:10.7554/elife.85415 · Cited by 44
Pathogenesis of idiopathic pulmonary fibrosis: review of recent findings
Renzoni, E. A., Veeraraghavan, S., & Sestini, P. (2014) · F1000Prime Reports · doi:10.12703/p6-69 · Cited by 60
“Even in the absence of TERT/ TERC mutations, a proportion of IPF patients have shorter telomeres compared with age-matched controls [17,18].”
Waisberg, D. R., Barbas‐Filho, J. V., Parra, E. R., Fernezlian, S., de Carvalho, C. R. R., Kairalla, R. A., & Capelozzi, V. L. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.08.019 · Cited by 47
“The ultimate conclusion of all these findings is that the fibrosis phenotype represents an irreversible loss of tissue renewal capacity, as a result of the reduction of the replicative potential of local progenitors cells, such as bone marrow aplasia, lung, and liver fibrosis [27-30].”
BackgroundKorfei, M., MacKenzie, B., & Meiners, S. (2020) · European Respiratory Review · doi:10.1183/16000617.0126-2020 · Cited by 45
Dai, J., Cai, H., Zhuang, Y., Wu, Y., Min, H., Li, J., Shi, Y. P., Gao, Q., & Yi, L. (2014) · Respirology · doi:10.1111/resp.12422 · Cited by 43
Cigarette smoking contributes to idiopathic pulmonary fibrosis associated with emphysema
Qiao, Y., Kewu, H., Ding, Y., Baohui, L., Ziliang, H., Huaping, D., Chen, W., & Mouyue, W. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20131684 · Cited by 42
“In addition, emphysema and pulmonary fibrosis are both aging associated diseases through severe telomere length shortening.(21)”
BackgroundLee, S. H., Yeo, Y., Kim, T., Lee, H. L., Lee, J. H., Park, Y. B., Park, J. S., Kim, Y. H., Song, J. W., Jhun, B. W., et al. (2019) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2018.0091 · Cited by 49
Genetic susceptibility and pulmonary fibrosis
Mathai, S. K., Schwartz, D. A., & Warg, L. A. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000074 · Cited by 39
“Interestingly, IPF patients have shortened telomeres even without the presence of known telomerase mutations [43,44], suggesting that there may be factors other than previously described mutations that affect telomere length and, by extension, risk of disease.”
BackgroundPermanent alveolar collapse is the predominant mechanism in idiopathic pulmonary fibrosis
Todd, N. W., Atamas, S. P., Luzina, I. G., & Galvin, J. R. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1067609 · Cited by 40
“Shortened telomeres and reduced telomerase expression are also observed in patients with sporadic IPF, although alternative mechanisms must be present since germline mutations of telomerase are rare in these patients [9,10].”
BackgroundGramatges, M. M., Qi, X., Sasa, G., Chen, J. J. ‐., & Bertuch, A. A. (2013) · Blood · doi:10.1182/blood-2012-08-447755 · Cited by 43
Self-citationMechanisms of pulmonary fibrosis: role of activated myofibroblasts and NADPH oxidase
Thannickal, V. J. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s23 · Cited by 41
“The enigma in many human highly lethal fibrotic disorders, in particular idiopathic pulmonary fibrosis (IPF), is the current, lack of understanding of: (1) the etiology of the apparent injury/infection, and (2) the progressive nature of the fibrotic process.”
BackgroundInfluentialTelomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis
Bilgili, H., Białas, A. J., Górski, P., & Piotrowski, W. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081232 · Cited by 40
“TERC Template in telomerase complex 602322 37a>g RNA P1b [38] 98g>a RNA P2b [37] 108c>u RNA P3 [50] 325g>u RNA P5 [47]”
BackgroundShimbori, C., Bellaye, P., Kolb, P., & Kolb, M. R. J. (2017) · Milestones in drug therapy · doi:10.1007/978-3-0348-0977-1_3 · Cited by 38
Cell Therapy Trials for Lung Diseases: Progress and Cautions
Weiss, D. J., & Ortiz, L. A. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201302-0351ed · Cited by 39
“TREM-2 has recently generated much interest in the field of Alzheimer’s disease, with the discovery of rare missense mutations that significantly increase susceptibility (2, 3).”
BackgroundInfluentialProgressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium
Bridges, J. P., Vladar, E. K., Kurche, J. S., Krivoi, A., Stancil, I. T., Dobrinskikh, E., Hu, Y., Sasse, S. K., Lee, J. S., Blumhagen, R. Z., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci183836 · Cited by 46
Xaubet, A., Ancochea, J., & Molina‐Molina, M. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.11.035 · Cited by 45
Insights from human genetic studies of lung and organ fibrosis
Garcia, C. K. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93556 · Cited by 40
“Only approximately 10% of sporadic IPF patients carry a rare qualifying variant in a telomererelated gene (4), yet a much higher percentage (25%–50%) have age-adjusted telomere lengths below the 10th percentile (43, 44).”
BackgroundExisting and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis
Inchingolo, R., Varone, F., Sgalla, G., & Richeldi, L. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1553620 · Cited by 37
“Alveolar epithelial cells and leukocytes from IPF patients have shorter telomeres, as compared with healthy agematched controls [61].”
BackgroundBarnes, P. J. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_3 · Cited by 40
Lynch, J. P., Fishbein, M. C., Saggar, R., Zisman, D. A., & Belperio, J. A. (2007) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.1.3.377 · Cited by 37
Gansner, J. M., & Rosas, I. O. (2013) · Translational research · doi:10.1016/j.trsl.2013.04.001 · Cited by 42
Selman, M., Martinez, F. J., & Pardo, A. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1166pp · Cited by 35
High-throughput STELA provides a rapid test for the diagnosis of telomere biology disorders
Norris, K., Walne, A. J., Ponsford, M., Cleal, K., Grimstead, J. W., Ellison, A., Alnajar, J., Dokal, I. S., Vulliamy, T., & Baird, D. M. (2021) · Human Genetics · doi:10.1007/s00439-021-02257-4 · Cited by 43
Medical genetics and epigenetics of telomerase
Koziel, J. E., Fox, M. J., Steding, C. E., Sprouse, A. A., & Herbert, B.-S. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01276.x · Cited by 36
Hoffman, H., Rice, C., & Skordalakes, E. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.771204 · Cited by 38
“Consistent with this hypothesis, it has been proposed that this mutation is also present in healthy subjects with telomere length within the normal range (16).”
BackgroundAt the stem of youth and health
Beltrami, A. P., Cesselli, D., & Beltrami, C. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.10.005 · Cited by 39
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations
Nakamura, Y., & Suda, T. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s39897 · Cited by 49
Xaubet, A., Ancochea, J., & Molina‐Molina, M. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2016.11.004 · Cited by 41
Lakota, K., Hanumanthu, V. S., Agrawal, R., Carns, M. A., Armanios, M. Y., & Varga, J. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214499 · Cited by 35
Self-citationZhang, C., Hansen, H. M., Semmes, E. C., Gonzalez‐Maya, J., Morimoto, L. M., Wei, Q., Eward, W. C., DeWitt, S. B., Hurst, J. H., Metayer, C., et al. (2019) · Bone · doi:10.1016/j.bone.2019.115070 · Cited by 40
Hong, X., Wang, L., Zhang, K., Liu, J., & Liu, J. (2022) · Cells · doi:10.3390/cells11050877 · Cited by 38
Piñeiro‐Hermida, S., Martínez, P., Bosso, G., Flores, J. M., Saraswati, S., Connor, J. R., Lemaire, R., & Blasco, M. A. (2022) · Nature Communications · doi:10.1038/s41467-022-32771-6 · Cited by 41
DeFilippis, R. A., Fordyce, C., Patten, K. T., Chang, H., Zhao, J., Fontenay, G., Kerlikowske, K. M., Parvin, B., & Tlsty, T. D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3390 · Cited by 39
“In addition to desmoplasia andHD, increased ECM is seen in other pathologic conditions associated with a DNA damage response (DDR) and/or telomere malfunction: fibrosis after g-irradiation (15), dyskeratosis congenita (16), and pulmonary (17) and liver fibrosis (18).”
Hadchouel, A., Marchand‐Martin, L., Franco‐Montoya, M., Peaudecerf, L., Ancel, P., Delacourt, C., & EPIPAGEADO study group (2015) · PLoS ONE · doi:10.1371/journal.pone.0136123 · Cited by 39
“A correlation was also found between TL obtained from peripheral blood and lung tissue in a study on pulmonary fibrosis [32].”
BackgroundLymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis
Glasgow, C. G., El‐Chemaly, S., & Moss, J. (2012) · European Respiratory Review · doi:10.1183/09059180.00009311 · Cited by 37
Genomics of Human Fibrotic Diseases: Disordered Wound Healing Response
Stone, R. C., Chen, V., Burgess, J. L., Pannu, S., & Tomic‐Canic, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228590 · Cited by 40
van Batenburg, A. A., Kazemier, K. M., van Oosterhout, M. F. M., van der Vis, J. J., Grutters, J. C., Goldschmeding, R., & van Moorsel, C. H. M. (2021) · ERJ Open Research · doi:10.1183/23120541.00691-2020 · Cited by 40
Interstitial Lung Diseases and Air Pollution: Narrative Review of Literature
Singh, N., & Singh, S. (2021) · Pulmonary Therapy · doi:10.1007/s41030-021-00148-7 · Cited by 40
Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis
Thong, L., McElduff, E. J., & Henry, M. T. (2023) · Life · doi:10.3390/life13020486 · Cited by 37
“Short telomeres reduce the tissue renewal capacity and telomeres shorten as an individual ages, which means that this could be the reason why the diagnosis of IPF has an age-related onset [17].”
BackgroundIdiopathic pulmonary fibrosis and the role of genetics in the era of precision medicine
Alonso-González, A., Tosco-Herrera, E., Molina‐Molina, M., & Flores, C. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1152211 · Cited by 46
Cellular Senescence: A Troy Horse in Pulmonary Fibrosis
Wan, R., Wang, L., Zhu, M., Li, W., Duan, Y., & Yu, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216410 · Cited by 36
“The dysfunction of telomeres in ATII cells exhibits characteristic features of cellular senescence, including the upregulation of cytokines involved in inflammation and immune response, thereby increasing susceptibility to PF [114,115].”
BackgroundPI3K/Akt in IPF: untangling fibrosis and charting therapies
Bhatt, J., Ghigo, A., & Hirsch, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1549277 · Cited by 41
Beghé, B., Cerri, S., Fabbri, L. M., & Marchioni, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179292 · Cited by 35
“In addition, shorter TLs have been described in lung alveolar type 2 (AT2) cells compared to controls [58]; interestingly, shorter TLs have also been described in AT2 cells in fibrotic areas compared to the non-fibrotic area in the same biopsy.”
BackgroundAging, antagonistic pleiotropy and fibrotic disease
Thannickal, V. J. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.05.010 · Cited by 32
Pulmonary Fibrosis in Children
Nathan, N., Siléo, C., Thouvenin, G., Berdah, L., Delestrain, C., Manali, E., Papiris, S. A., Léger, P., Pointe, H. D. L., L’Herminé, A. C., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091312 · Cited by 33
“With increasing age, the limited life span of cells may thus result from a limited cell replicative ability in response to various stresses, including DNA damage, oxidants, and telomere erosion [65,66].”
BackgroundCellular Aging Characteristics and Their Association with Age-Related Disorders
Rudzińska, M., Parodi, A., Balakireva, A. V., Chepikova, O. E., Venanzi, F. M., & Zamyatnin, A. A. (2020) · Antioxidants · doi:10.3390/antiox9020094 · Cited by 39
Molecular and Genetic Biomarkers in Idiopathic Pulmonary Fibrosis: Where Are We Now?
Tomos, I. P., Roussis, I., Matthaiou, A. Μ., & Dimakou, K. (2023) · Biomedicines · doi:10.3390/biomedicines11102796 · Cited by 40
Jackson, S.-R., Lee, J., Reddy, R., Williams, G. N., Kikuchi, A., Freiberg, Y., Warburton, D., & Driscoll, B. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00409.2010 · Cited by 33
“In lung, telomerase mutations have been linked to idiopathic pulmonary fibrosis of the lung (IPF) (2, 4, 22, 57), a condition hypothesized to be initiated in some cases by epithelial hypoplasia (35, 53).”
BackgroundMahansaria, S. S., Kumar, S., V, Bharathy, K. G. S., Kumar, S. A., & Pamecha, V. (2015) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2015.10.003 · Cited by 32
“Pulmonary complications are reported in 20% of patients with DKC.(12) ILD has also been described with DKC after BMT.”
BackgroundInfluentialSnetselaar, R., van Oosterhout, M. F. M., Grutters, J. C., & van Moorsel, C. H. M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00041 · Cited by 34
van Batenburg, A. A., Kazemier, K. M., van Oosterhout, M. F. M., van der Vis, J. J., van Es, H. W., Grutters, J. C., Goldschmeding, R., & van Moorsel, C. H. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226785 · Cited by 34
The Dawn of Precision Medicine in Fibrotic Interstitial Lung Disease
Karampitsakos, Τ., Tourki, B., & Herazo‐Maya, J. D. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.10.042 · Cited by 32
“14 Finally, rare protein-altering variants in TERT , TERC , PARN , and RTEL1 are more frequent in patients with IPF compared with control participants.”
Zolak, J. S., & de Andrade, J. A. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.08.006 · Cited by 38
Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deep sequencing
Lorenzo-Salazar, J. M., Ma, S., Jou, J., Hou, P., Guillén‐Guío, B., Allen, R. J., Jenkins, G. R., Wain, L. V., Oldham, J. M., Noth, I., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00071-2019 · Cited by 34
Rare surfactant‐related variants in familial and sporadic pulmonary fibrosis
Sutton, R. M., Bittar, H. E. T., Sullivan, D. I., Silva, A. G., Bahudhanapati, H., Parikh, A. H., Zhang, Y., Gibson, K. F., McDyer, J. F., Kass, D. J., et al. (2022) · Human Mutation · doi:10.1002/humu.24476 · Cited by 36
“Short telomeres in the absence of an identifiable causal genetic variant are also known to be a risk factor for the development of pulmonary fibrosis in patients with both familial as well as sporadic disease (Alder et al., 2008; Cronkhite et al., 2008).”
Self-citationLiu, T., Yu, H., Ding, L., Wu, Z. B., Santos, F. G. D. L., Liu, J., Ullenbruch, M. R., Hu, B., Martins, V., & Phan, S. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142547 · Cited by 33
“While telomerase is significantly induced in lung fibroblasts from rodents with pulmonary fibrosis as well as a majority of patients with fibrotic interstitial lung diseases, including IPF [33], shortened telomeres in peripheral blood leukocytes have been reported in familial IPF and a minority of patients with sporad…”
BackgroundRetuerto, M., Lledó, A., Fernández-Varas, B., Guerrero, R., Usategui, A., Lalueza, A., García-García, R., Mancebo, E., Paz‐Artal, E., Sastre, L., et al. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00294-9 · Cited by 30
“Although COVID19 may lead to lung fibrotic changes after the acute phase, lung function tends to improve and a progressive fibrosis similar to IPF is not observed [28].”
BackgroundInfluentialTelomere dysfunction in human diseases: the long and short of it!
Carroll, K. A., & Ly, H. (2009) · Europe PMC (PubMed Central) · Cited by 39
Advances in cellular senescence in idiopathic pulmonary fibrosis (Review)
Han, S., Lu, Q., & Liu, X. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11844 · Cited by 34
Yang, M. M., Lee, S., Neely, J. A., Hinchcliff, M., Wolters, P. J., & Sirota, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1326922 · Cited by 35
“Aberrant aging as a driver of pulmonary disease has been well established in several lung diseases including IPF and COPD; however, its role in SSc-ILD remains less clear (11, 33, 34).”
BackgroundLymphatics in Idiopathic Pulmonary Fibrosis: New Insights into an Old Disease
El‐Chemaly, S., Pacheco–Rodriguez, G., Ikeda, Y., Malide, D. A., & Moss, J. (2009) · Lymphatic Research and Biology · doi:10.1089/lrb.2009.0014 · Cited by 31
“While the mechanism of injury is unclear, recent evidence suggests the importance of genetic background in the pathogenesis of disease.(6,7) The long-prevailing hypothesis is that IPF represents a disease of chronic inflammation that results in a persistent antigenic response, leading to fibrosis.”
Pulmonary Fibrosis, Bone Marrow Failure, and Telomerase Mutation
Gansner, J. M., Rosas, I. O., & Ebert, B. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1200999 · Cited by 29
Morphology of the Aging Lung on Computed Tomography
Copley, S. J. (2016) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000211 · Cited by 31
Update on diffuse parenchymal lung disease
Harari, S. A., & Caminati, A. (2010) · European Respiratory Review · doi:10.1183/09059180.00002510 · Cited by 31
Hannan, S. J., Iasella, C. J., Sutton, R. M., Popescu, I., Koshy, R., Burke, R., Chen, X., Zhang, Y., Pilewski, J. M., Hage, C. A., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.06.014 · Cited by 31
Self-citationIskandar, M., Barbero, M. X., Jaber, M. T., Chen, R., Gomez-Guevara, R., Cruz, E., & Westerheide, S. D. (2025) · Cancers · doi:10.3390/cancers17020257 · Cited by 34
The Idiopathic Interstitial Pneumonias
Hobbs, S., & Lynch, D. A. (2013) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2013.08.001 · Cited by 29
Hecker, L., & Thannickal, V. J. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31821a9d66 · Cited by 33
Waisberg, D. R., Parra, E. R., Barbas‐Filho, J. V., Fernezlian, S., & Capelozzi, V. L. (2012) · Clinics · doi:10.6061/clinics/2012(09)10 · Cited by 30
“In light of these (10) and other recent findings implicating telomerase in IPF pathogenesis (11-14), we sought to study”
BackgroundPiotrowski, W. J., Bestry, I., Białas, A. J., Boros, P. W., Grzanka, P., Jassem, E., Jastrzębski, D., Klimczak, D., Langfort, R., Lewandowska, K. B., et al. (2020) · Advances in respiratory medicine · doi:10.5603/arm.2020.0081 · Cited by 32
Auld, S. C., Sheshadri, A., Alexander‐Brett, J. M., Aschner, Y., Barczak, A. K., Basil, M. C., Cohen, K. A., Cruz, C. S. D., McGroder, C. F., Restrepo, M. I., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202406-651st · Cited by 29
“Of the genetic factors associated with IPF, telomere shortening (251, 252), with or without rare telomere mutations (253, 254), and the MUC5B promoter polymorphism rs35705950 (51) may also play a role in fi brosis associated with COVID-19.”
Pulmonary fibrosis in non‐mutation carriers of families with short telomere syndrome gene mutations
van der Vis, J. J., van der Smagt, J. J., van Batenburg, A. A., Goldschmeding, R., van Es, H. W., Grutters, J. C., & van Moorsel, C. H. M. (2021) · Respirology · doi:10.1111/resp.14145 · Cited by 29
“Progeny of TRG mutation carriers had short telomeres, whether the TRG mutation was inherited.3,23 Moreover, a family study on the origin of a TERT founder mutation underlines the notion that short telomeres are the primary cause of disease development.11 In addition, short telomeres are a common feature of IPF.9,10,24…”
BackgroundInterstitial lung disease: Physiopathology in the context of lung growth
Nathan, N., Thouvenin, G., Fauroux, B., Corvol, H., & Clément, A. (2011) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2011.04.003 · Cited by 28
Evolving Genomic Approaches to Idiopathic Pulmonary Fibrosis: Moving Beyond Genes
Kass, D. J., & Kaminski, N. (2011) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2011.00287.x · Cited by 29
Long-term ozone exposure is positively associated with telomere length in critically ill patients
Wang, C., Wolters, P. J., Calfee, C. S., Liu, S., Balmes, J. R., Zhao, Z., Koyama, T., & Ware, L. B. (2020) · Environment International · doi:10.1016/j.envint.2020.105780 · Cited by 30
Naikawadi, R. P., Green, G., Jones, K. D., Achtar‐Zadeh, N., Mieleszko, J. E., Arnould, I. S., Kukreja, J., Greenland, J. R., & Wolters, P. J. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0374oc · Cited by 28
“Short telomeres are evident in diseases of tissue remodeling and fibrosis, including skin dyskeratosis (26), hypertrophic cardiomyopathy (27–29), liver cirrhosis (30), Duchenne muscular dystrophy (31), idiopathic pulmonary fibrosis (32), and CLAD (9, 10).”
BackgroundClinical Impact of Telomere Length Testing for Interstitial Lung Disease
Zhang, D., Eckhardt, C. M., McGroder, C. F., Benesh, S., Porcelli, J., Depender, C., Bogyo, K., Westrich, J. A., Thomas‐Wilson, A., Jobanputra, V., et al. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.06.006 · Cited by 27
Ozdemir, S. A., Faizan, M. I., Kaur, G., Shaikh, S. B., Islam, K. U., & Rahman, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199687 · Cited by 34
Zhang, Y., Jones, K. D., Achtar‐Zadeh, N., Green, G., Kukreja, J., Xu, B., & Wolters, P. J. (2019) · Histopathology · doi:10.1111/his.13745 · Cited by 26
Liang, L., Cai, Y. S., Lyu, B., Zhang, D., Chu, S., Jing, H., Rahimi, K., & Tong, Z. (2022) · Respiratory Research · doi:10.1186/s12931-022-01998-8 · Cited by 28
“Numerous mechanistic studies have indicated that PM could cause oxidative stress via over-production of reactive oxygen species [2, 24], which eventually leads to cellular damage and shortened telomeres, a recognized risk factor of IPF [27].”
BackgroundPlasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis
Sari, E., He, C., & Margaroli, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911443 · Cited by 29
Clinical Genetics in Interstitial Lung Disease
Newton, C. A., Molyneaux, P. L., & Oldham, J. M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00116 · Cited by 29
“Short telomere length is relatively common in both of these diseases, 23–50% of patients with sporadic IPF and 24% of CHP patients have age-adjusted telomere length less than 10th percentile (46, 51, 30).”
BackgroundLv, M., Liu, Y., Ma, S., & Yu, Z. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0111 · Cited by 27
Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice
Schratz, K. E., & Dezern, A. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.10.002 · Cited by 26
Hao, J., Hu, R., Zhao, J., Li, Y., Li, Q., & Zhang, X. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156032 · Cited by 27
Emerging drugs for idiopathic pulmonary fibrosis
Selman, M., Pardo, A., Richeldi, L., & Cerri, S. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.565049 · Cited by 29
“Heterozygous loss-offunction mutations in the human telomerase genes have been associated in close to 10% of familial IPF [41-43].”
BackgroundThe world of rare interstitial lung diseases
Buschulte, K., Cottin, V., Wijsenbeek, M. S., Kreuter, M., & Diesler, R. (2023) · European Respiratory Review · doi:10.1183/16000617.0161-2022 · Cited by 27
“Additionally, telomere-related mutations account for ∼ 10% of sporadic cases of pulmonary fibrosis [93, 97, 98] and 12% of rheumatoid arthritis-associated ILD [99].”
Chiba, S., Ohta, H., Abe, K., Hisata, S., Ohkouchi, S., Hoshikawa, Y., Kondo, T., & Ebina, M. (2012) · Pulmonary Medicine · doi:10.1155/2012/492960 · Cited by 26
“Shortened telomeres are a risk factor for IPF and are associated with COPD and lung cancer [13–15].”
BackgroundMagnini, D., Montemurro, G., Iovene, B., Tagliaboschi, L., Gerardi, R. E., Greco, E. L., Bruni, T., Fabbrizzi, A., Lombardi, F., & Richeldi, L. (2017) · Respiration · doi:10.1159/000475780 · Cited by 26
Wang, H., Zhuang, Y., Peng, H., Cao, M., Li, Y., Xu, Q., Xin, X., Zhou, K., Liang, G., Cai, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51902-6 · Cited by 28
Lynch, J. P., & Belperio, J. A. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9771-5_10 · Cited by 26
Metadata
- Authors
- Alder, J. K., Chen, J. J.-L., Lancaster, L., Danoff, S., Su, S.-C., Cogan, J. D., Vulto, I., Xie, M., Qi, X., Tuder, R. M., Phillips, J. A., Lansdorp, P. M., Loyd, J. E., & Armanios, M. Y.
- Affiliations
- Johns Hopkins University (US)
- Arizona State University (US)
- Vanderbilt University (US)
- BC Cancer Agency (CA)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-09-02
- Volume
- 105
- Issue
- 35
- Pages
- 13051-13056
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2529100
- OpenAlex
- W2147238277
- Cited by
- 805
- References
- 35
- Citations by year
- 2026: 32 · 2025: 40 · 2024: 38 · 2023: 48 · 2022: 45 · 2021: 61 · 2020: 53 · 2019: 60 · 2018: 54 · 2017: 40 · 2016: 36 · 2015: 56 · 2014: 45 · 2013: 45 · 2012: 40
- FWCI
- 33.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Doris Duke Charitable Foundation
- Johns Hopkins University
- National Institutes of Health
- U.S. Public Health Service (T32 60441, K08 118416)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, telomere length, short telomeres, telomerase mutations, hTERT, hTR, leukocytes, alveolar epithelial cells, cryptogenic cirrhosis, disease risk
- MeSH terms
- Epithelium, Family, Fibrosis, Heterozygote, Humans, Leukocytes, Mononuclear, Pulmonary Alveoli, Pulmonary Fibrosis, Risk Factors, RNA, Tomography, X-Ray Computed, Biomarkers, Case-Control Studies, Telomere, In Situ Hybridization, Fluorescence, Germ-Line Mutation, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.